Market Access/ News/ News After FDA approval, Alkermes plans soft launch for antipsychotic Lybalvi Phil Taylor Alkermes, bipolar disorder, FDA approval, Lybalvi, Psychiatry, schizophrenia 0 Comment The FDA approval of Alkermes’ new antipsychotic drug Lybalvi couldn’t have gone any better for the company, but Share X After FDA approval, Alkermes plans soft launch for antipsychotic Lybalvi https://pharmaphorum.com/news/after-fda-approval-alkermes-plans-soft-launch-for-antipsychotic-lybalvi/